Amanda Cole
Amanda is a health economist specialising in economic evaluation, reimbursement, real-world evidence, and health policy. She leads OHE’s Economics of Innovation theme and is an Honorary Professor of Practice at UCL and a member of ISPOR’s Health Science Policy Council.
Her research focuses on value-based payment models, incentives for innovation, pharmaceutical market design, and the intersection of HTA policy and R&D decisions. She is particularly interested in how drug development innovations require new reimbursement models, especially for multi-indication therapies, precision medicine, and gene therapies. She is keen to advance a research agenda for how real-world evidence can improve healthcare technology development and adoption.
Amanda has a special interest in rare diseases and serves on several advisory groups, including Genetic Alliance UK’s Patient Empowerment Group, England’s Rare Disease Action Plan Advisory Group, and the Study Steering Committee for CONCORD2. Before OHE, Amanda was a research fellow at the University of Birmingham, where she earned her PhD in Health Economics in 2013.
Publications and Insights
- Insight: The Trump Administration’s US Drug Pricing Proposal – What will happen next?
- Insight: Advancing Rare Disease Care: Challenges and Key Issues
- Publication: The Importance of Diversity of Supply in Rare Diseases Markets
- Publication: Employer Costs from Respiratory Infections
- Insight: What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
- Publication: The Cost of Drug Shortages
- Insight: Drug shortages are on the rise – but what is their impact?
- Publication: A Framework for Value-aligned Pricing of Combination Therapies
- Insight: Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
- Insight: Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
- Insight: Rare Disease Day 2024: Why Do We Care About Rare?
- Publication: The Dynamics of Drug Shortages
- Insight: The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
- Publication: Are Recommendations for HTA of Gene Therapies Being Achieved?
- Bulletin: The Inflation Reduction Act has landed
- Insight: The US Inflation Reduction Act: What Do the Experts Think?
- Publication: Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
- Publication: Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
- Publication: Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
- Publication: Payment Models for Multi-Indication Therapies
- Publication: NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
- Publication: Indication-Based Pricing (IBP) Consultation Report
- Publication: Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
- Publication: Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
- Publication: Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
- Publication: Making Outcome-Based Payment a Reality in the NHS
- Publication: Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation
- Publication: Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
- Publication: The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
- Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom
- Publication: Data Governance Arrangements for Real-World Evidence: South Korea
- Publication: An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’
- Publication: Improving Efficiency and Resource Allocation in Future Cancer Care
- Publication: “New Age” Decision Making in HTA: Is It Applicable in Asia?
- Publication: How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
- Publication: A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
- Publication: Data Governance Arrangements for Real-World Evidence
- Publication: Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
- Publication: Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?